(Q82606081)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20093205%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20093205%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

main subject

visceral leishmaniasis

1 reference

Rajeev Nagill

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20093205%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Sukhbir Kaur

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20093205%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

19 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20093205%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20093205%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20093205%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20093205%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

4002-4012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20093205%20AND%20SRC:MED&resulttype=core&format=json

Leishmaniasis: current situation and new perspectives

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Vaccines against leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Development of a safe live Leishmania vaccine line by gene replacement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Immunization with recombinant LD1 antigens protects against experimental leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Leishmania major infection in susceptible and resistant mice elicit a differential humoral response against a total soluble fraction and defined recombinant antigens of the parasite

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Speculations on the functions of the major heat shock and glucose-regulated proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

S. cerevisiae encodes an essential protein homologous in sequence and function to mammalian BiP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

KAR2, a karyogamy gene, is the yeast homolog of the mammalian BiP/GRP78 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

The genome of the kinetoplastid parasite, Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Comparative genomic analysis of three Leishmania species that cause diverse human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani(1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Recent developments in adjuvants for vaccines against infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Liposomes as vaccine carriers. Incorporation of soluble and particulate antigens in giant vesicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Vaccine entrapment in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Antileishmanial activity of an indole alkaloid from Peschiera australis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Ability of macrophage subsets to transfer resistance to murine leishmaniasis is dependent on IL-12 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Leishmania major: common antigen responsible for induction of delayed-type hypersensitivity response in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

General suppression of macrophage gene expression during Leishmania donovani infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Effect of dose and route of inoculation on the generation of CD4+ Th1/Th2 type of immune response in murine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-gamma production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Interleukin 10 production correlates with pathology in human Leishmania donovani infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

T-cell response in human leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

IL-10 mediates susceptibility to Leishmania donovani infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Humoral and Cellular Immune Responses to Synthetic Peptides of the Leishmania donovani Kinetoplastid Membrane Protein-11

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.01.015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20093205%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference